BioMimetic Therapeutics (BMTI): Deutsche Bank reits Buy and $22 tgt - Actionable Call Alert
BMTI Hot Sheet
Rating Summary:2 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
From Notable Calls
Deutsche Bank out positive on BioMimetic Therapeutics (NASDAQ: BMTI) saying they conducted a due diligence call with Dr. Jeffrey Wieman, the Lead Investigator for the Regranex pivotal study and involved with the product since its preclinical days, to discuss recent concerns over potential Regranex cancer deaths. Based on all his work with Regranex, Dr. Weiman does not believe there is a causal relationship between Regranex (or PDGF) and carcinogenesis/cancer deaths. Also, he is actually a cancer expert and CEO of St. Luke's Cancer Institute (Univ. of Missouri) and understands the nuances of cancer mechanism/science.
Firm continues to believe FDA's Regranex safety review will not materially impact BMTI's GEM OS1 clinical/regulatory outlook given the poor clinical/scientific link between recombinant PDGF and cancer.
Reiterates Buy and $22 tgt.
Notablecalls: You gotta buy BMTI here. Based on DB's call the stock deserves to trade around $11-$12 here. Going to call it Actionable Trading Call.
For more calls go to http://notablecalls.blogspot.com/
Deutsche Bank out positive on BioMimetic Therapeutics (NASDAQ: BMTI) saying they conducted a due diligence call with Dr. Jeffrey Wieman, the Lead Investigator for the Regranex pivotal study and involved with the product since its preclinical days, to discuss recent concerns over potential Regranex cancer deaths. Based on all his work with Regranex, Dr. Weiman does not believe there is a causal relationship between Regranex (or PDGF) and carcinogenesis/cancer deaths. Also, he is actually a cancer expert and CEO of St. Luke's Cancer Institute (Univ. of Missouri) and understands the nuances of cancer mechanism/science.
Firm continues to believe FDA's Regranex safety review will not materially impact BMTI's GEM OS1 clinical/regulatory outlook given the poor clinical/scientific link between recombinant PDGF and cancer.
Reiterates Buy and $22 tgt.
Notablecalls: You gotta buy BMTI here. Based on DB's call the stock deserves to trade around $11-$12 here. Going to call it Actionable Trading Call.
For more calls go to http://notablecalls.blogspot.com/
You May Also Be Interested In
- Barclays Maintains an 'Overweight' on Tidewater (TDW); Dayrates Climb, But Adjusting Numbers Lower on Expenses
- Nomura Securities Maintains a 'Neutral' on Yahoo! (YHOO); Monetizing Alibaba
- Barclays maintains an 'Equalweight' on Tech Data (TECD); Slight Adjustments on Q1 Results
Create E-mail Alert Related Categories
Analyst Comments, ContributorsRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
